Literature DB >> 30878146

Recall accuracy for the symptoms of a major depressive episode among clinical trial participants.

Boadie W Dunlop1, Maria Granros2, Amber Lechner3, Tanja Mletzko-Crowe3, Charles B Nemeroff4, Helen S Mayberg5, W Edward Craighead6.   

Abstract

For patients with major depressive disorder (MDD), approaches to treatment differ for those with a single versus recurrent episodes. Based on studies of community samples, however, accuracy is low for identifying past episodes. Recall accuracy among clinical samples with a well-defined major depressive episode (MDE) has not been examined previously. We evaluated episode recall accuracy in 79 MDD patients in follow-up of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study at 12- and 24-month time-points after starting treatment. Using the Structured Clinical Interview for DSM-IV, patients were asked to recall whether they had been experiencing the nine criterion symptoms of an MDE at the time of their intake assessment. Accuracy of recall for the index MDE was high, with 95% of patients at month 12 and 85% at month 24 recalling sufficient symptoms to meet the diagnostic criteria. Recall accuracy for specific symptoms varied considerably, from >90% for dysphoria and anhedonia, to 55% for psychomotor and weight/appetite changes. For the thoughts of death/suicide criterion, patients with erroneous recall were significantly more likely to recall having had the symptom at the intake evaluation (though they had denied it at the time) than vice versa (p < .007). Patients who have participated in a clinical trial are likely to recall accurately a past MDE up to two years prior. Optimal vigilance for suicidal ideation for treatment-naïve patients should include a combination of self-report and clinician assessments.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anhedonia; Antidepressant; CBT; Depression; Dysphoria; Suicide

Year:  2019        PMID: 30878146     DOI: 10.1016/j.jpsychires.2019.03.008

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  4 in total

1.  Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression.

Authors:  Hua-Hsin Tai; Jungho Cha; Faezeh Vedaei; Boadie W Dunlop; W Edward Craighead; Helen S Mayberg; Ki Sueng Choi
Journal:  Front Psychiatry       Date:  2021-12-24       Impact factor: 4.157

2.  Comparing the associations of three psychometric scales at baseline with long-term prognosis of depression over a 10-year period.

Authors:  Ching-I Hung; Chia-Yih Liu; Shih-Chieh Hsu; Ching-Hui Yang
Journal:  Int J Methods Psychiatr Res       Date:  2021-10-29       Impact factor: 4.035

3.  The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

Authors:  Lucie Bartova; Gernot Fugger; Markus Dold; Alexander Kautzky; Marleen Margret Mignon Swoboda; Dan Rujescu; Joseph Zohar; Daniel Souery; Julien Mendlewicz; Stuart Montgomery; Chiara Fabbri; Alessandro Serretti; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

4.  The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.

Authors:  Gernot Fugger; Lucie Bartova; Chiara Fabbri; Giuseppe Fanelli; Markus Dold; Marleen Margret Mignon Swoboda; Alexander Kautzky; Joseph Zohar; Daniel Souery; Julien Mendlewicz; Stuart Montgomery; Dan Rujescu; Alessandro Serretti; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-06       Impact factor: 5.760

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.